Advanced search
Publication Cover
Expert Review of Vaccines Volume 13, 2014 - Issue 1
Submit an article Journal homepage
274
Views
3
CrossRef citations to date
0
Altmetric
Reviews

Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer

Mehrdad Talebian YazdiDepartment of Pulmonology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
,
Kevin R KeeneDepartment of Clinical Oncology, Leiden University Medical Center (LUMC), Building 1, K1-P, PO box 9600, 2300 RC Leiden, the Netherlands
,
Pieter S HiemstraDepartment of Pulmonology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
&
Sjoerd H van der BurgDepartment of Clinical Oncology, Leiden University Medical Center (LUMC), Building 1, K1-P, PO box 9600, 2300 RC Leiden, the NetherlandsCorrespondence[email protected]
Pages 87-116 | Published online: 26 Nov 2013

References

  • Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs 71(1), 101–108 (2011).
  • Culver ME, Gatesman ML, Mancl EE, Lowe DK. Ipilimumab: a novel treatment for metastatic melanoma. Ann. Pharmacother. 45(4), 510–519 (2011).
  • Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  • Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
  • Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  • Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).
  • Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23( Suppl. 8), viii6–viii9 (2012).
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  • Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8(5), 351–360 (2008).
  • Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70(21), 8368–8377 (2010).
  • Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15(3), 1086–1095 (2009).
  • Leffers N, Lambeck AJ, Gooden MJ et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int. J. Cancer 125(9), 2104–2113 (2009).
  • Welters MJ, Kenter GG, Piersma SJ et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14(1), 178–187 (2008).
  • Kenter GG, Welters MJ, Valentijn AR et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14(1), 169–177 (2008).
  • Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838–1847 (2009).
  • Welters MJ, Kenter GG, de Vos van Steenwijk PJ et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl Acad. Sci. USA 107(26), 11895–11899 (2010).
  • Kast WM, Roux L, Curren J et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl Acad. Sci. USA 88(6), 2283–2287 (1991).
  • Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev. Vaccines 6(4), 591–603 (2007).
  • van Hall T, van der Burg SH. Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. Adv. Immunol. 114, 51–76 (2012).
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012).
  • Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367–1380 (2008).
  • Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst. Rev. 2, 10 (2013).
  • Altieri DC. Targeting survivin in cancer. Cancer Lett. 332(2), 225–228 (2013).
  • Becker JC, Andersen MH, Hofmeister-Muller V et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol. Immunother. 61(11), 2091–2103 (2012).
  • Miyazaki A, Kobayashi J, Torigoe T et al. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 102(2), 324–329 (2011).
  • Kameshima H, Tsuruma T, Kutomi G et al. Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 104(1), 124–129 (2013).
  • Kameshima H, Tsuruma T, Torigoe T et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 102(6), 1181–1187 (2011).
  • Yoshikawa T, Nakatsugawa M, Suzuki S et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci. 102(5), 918–925 (2011).
  • Sawada Y, Yoshikawa T, Nobuoka D et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin. Cancer Res. 18(13), 3686–3696 (2012).
  • Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin. Oncol. 28( 6 Suppl. 18), 12–20 (2001).
  • Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10), 2594–2602 (2012).
  • Yoshimura K, Minami T, Nozawa M, Uemura H. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br. J. Cancer 108(6), 1260–1266 (2013).
  • Hayashi H, Kurata T, Fujisaka Y et al. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. Cancer Sci. 104(1), 98–104 (2013).
  • Okamoto I, Arao T, Miyazaki M et al. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 103(12), 2135–2138 (2012).
  • Kawaguchi S, Tsukahara T, Ida K et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 103(9), 1625–1630 (2012).
  • Vetsika EK, Konsolakis G, Aggouraki D et al. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Cancer Immunol. Immunother. 61(2), 157–168 (2012).
  • Kotsakis A, Vetsika EK, Christou S et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann. Oncol. 23(2), 442–449 (2012).
  • Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323–5337 (2009).
  • Miyatake T, Ueda Y, Morimoto A et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J. Cancer Res. Clin. Oncol. 139(3), 457–463 (2013).
  • Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Phase I trial of Wilms’ Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 32(6), 2263–2269 (2012).
  • Obara W, Ohsawa R, Kanehira M et al. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J. Clin. Oncol. 42(7), 591–600 (2012).
  • Kono K, Iinuma H, Akutsu Y et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J. Transl. Med. 10, 141 (2012).
  • Ishikawa H, Imano M, Shiraishi O et al. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer doi:10.1007/s10120-013-0258-6 (2013) ( Epub ahead of print).
  • Tarhini AA, Leng S, Moschos SJ et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J. Immunother. 35(4), 359–366 (2012).
  • Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res. 15(4), 1443–1451 (2009).
  • Schaefer C, Butterfield LH, Lee S et al. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int. J. Cancer 131(4), 874–884 (2012).
  • Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119–2127 (2011).
  • Block MS, Suman VJ, Nevala WK et al. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res. 21(5), 438–445 (2011).
  • Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol. Immunother. 62(5), 919–929 (2013).
  • Noguchi M, Moriya F, Suekane S et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 72(8), 834–845 (2012).
  • Terazaki Y, Yoshiyama K, Matsueda S et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci. 103(4), 638–644 (2012).
  • Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J. Clin. Oncol. 29(3), 337–344 (2011).
  • Welters MJ, Kenter GG, de Vos van Steenwijk PJ et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl Acad. Sci. USA 107(26), 11895–11899 (2010).
  • Goldinger SM, Dummer R, Baumgaertner P et al. Nano-particle vaccination combined with TLR-7 and −9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur. J. Immunol. 42(11), 3049–3061 (2012).
  • Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 10(6), 443–448 (1998).
  • Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol. Lett. 74(1), 75–79 (2000).
  • Hunger RE, Kernland LK, Markowski CJ et al. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol. Immunother. 60(11), 1553–1564 (2011).
  • Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 154–1261 (2012).
  • Weden S, Klemp M, Gladhaug IP et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int. J. Cancer 128(5), 1120–1128 (2011).
  • Sonpavde G, Wang M, Peterson LE et al. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest. New Drugs doi:10.1007/s10637-013-9960-9 (2013) ( Epub ahead of print).
  • Sabbatini P, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18(23), 6497–6508 (2012).
  • Kakimi K, Isobe M, Uenaka A et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int. J. Cancer 129(12), 2836–2846 (2011).
  • Eikawa S, Kakimi K, Isobe M et al. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91–110) peptide. Int. J. Cancer 132(2), 345–54.
  • de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol. Immunother. 61(9), 1485–1492 (2012).
  • van Poelgeest MI, Welters MJ, van Esch EM et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J. Transl. Med. 11, 88 (2013).
  • Zeestraten EC, Speetjens FM, Welters MJ et al. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int. J. Cancer 132(7), 1581–1591 (2013).
  • Voskens CJ, Sewell D, Hertzano R et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 34(12), 1734–1746 (2012).
  • Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol. 8(10), 1273–1299 (2012).
  • Aarntzen EH, De Vries IJ, Lesterhuis WJ et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 73(1), 19–29 (2013).
  • Lesterhuis WJ, De Vries IJ, Schreibelt G et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 17(17), 5725–5735 (2011).
  • Tel J, Aarntzen EH, Baba T et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 73(3), 1063–1075 (2013).
  • Akiyama Y, Tanosaki R, Inoue N et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J. Transl. Med. 3(1), 4 (2005).
  • Oshita C, Takikawa M, Kume A et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol. Rep. 28(4), 1131–1138 (2012).
  • Romano E, Rossi M, Ratzinger G et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin. Cancer Res. 17(7), 1984–1997 (2011).
  • Phuphanich S, Wheeler CJ, Rudnick JD et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol. Immunother. 62(1), 125–135 (2013).
  • Rahma OE, Ashtar E, Czystowska M et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol. Immunother. 61(3), 373–384 (2012).
  • Sharma A, Koldovsky U, Xu S et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118(17), 4354–4362 (2012).
  • Koski GK, Koldovsky U, Xu S et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35(1), 54–65 (2012).
  • Rong Y, Qin X, Jin D et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin. Exp. Med. 12(3), 173–180 (2012).
  • Sakakibara M, Kanto T, Hayakawa M et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol. Immunother. 60(11), 1565–1575 (2011).
  • Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330–336 (2011).
  • Akiyama Y, Oshita C, Kume A et al. alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer 12, 623 (2012).
  • Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol. Immunother. 57(11), 1579–1587 (2008).
  • Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59–73 (2008).
  • Kang TH, Mao CP, Lee SY et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 73(8), 2493–2504 (2013).
  • Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol. Ther. 6(6), 880–885 (2007).
  • Kaida M, Morita-Hoshi Y, Soeda A et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J. Immunother. 34(1), 92–99 (2011).
  • Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin. Cancer Res. 17(13), 4568–4580 (2011).
  • Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71(5), 470–479 (2011).
  • Leffers N, Vermeij R, Hoogeboom BN et al. Long-term clinical and immunological effects of p53-SLP(R) vaccine in patients with ovarian cancer. Int. J. Cancer 130(1), 105–112 (2012).
  • Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 72(14), 3439–3444 (2012).
  • Camisaschi C, Filipazzi P, Tazzari M et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol. Immunother. 62(5), 897–908 (2013).
  • Filipazzi P, Pilla L, Mariani L et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin. Cancer Res. 18(23), 6485–6496 (2012).
  • Slingluff CL, Jr., Petroni GR, Chianese-Bullock KA et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J. Clin. Oncol. 29(21), 2924–2932 (2011).
  • Vermeij R, Leffers N, Hoogeboom BN et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int. J. Cancer 131(5), e670–e680 (2012).
  • Chu CS, Boyer J, Schullery DS et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol. Immunother. 61(5), 629–641 (2012).
  • Sarnaik AA, Yu B, Yu D et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 17(4), 896–906 (2011).
  • Azzoli CG, Temin S, Aliff T et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 29(28), 3825–3831 (2011).
  • O’Rourke N, Roque IF, Farre BN, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. (6), CD002140 (2010).
  • Smolle-Juettner FM, Maier A, Lindenmann J, Matzi V, Neubock N. Resection in stage I/II non-small cell lung cancer. Front. Radiat. Ther. Oncol. 42, 71–77 (2010).
  • Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382(9893), 720–731 (2013).
  • Bremnes RM, Al-Shibli K, Donnem T et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J. Thorac. Oncol. 6(4), 824–833 (2011).
  • Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10, 112 (2010).
  • Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 33(1), 118–126 (2009).
  • Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer. Res. 14(16), 5220–5227 (2008).
  • Wakabayashi O, Yamazaki K, Oizumi S et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 94(11), 1003–1009 (2003).
  • Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J. Thorac. Oncol. 5(5), 585–590 (2010).
  • Petersen RP, Campa MJ, Sperlazza J et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107(12), 2866–2872 (2006).
  • Suzuki H, Fukuhara M, Yamaura T et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J. Transl. Med. 11(1), 97 (2013).
  • Yoshiyama K, Terazaki Y, Matsueda S et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int. J. Oncol. 40(5), 1492–1500 (2012).
  • Takahashi H, Okamoto M, Shimodaira S et al. Impact of dendritic cell vaccines pulsed with Wilms’ tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur. J. Cancer 49(4), 852–859 (2013).
  • Perroud MW, Jr., Honma HN, Barbeiro AS et al. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J. Exp. Clin. Cancer Res. 30, 65 (2011).
  • Brunsvig PF, Kyte JA, Kersten C et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin. Cancer Res. 17(21), 6847–6857 (2011).
  • Brunsvig PF, Aamdal S, Gjertsen MK et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 55(12), 1553–1564 (2006).
  • Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137(9), 1337–1342 (2011).
  • Ohyanagi F, Horai T, Sekine I et al. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. Jpn J. Clin. Oncol. 41(5), 718–722 (2011).
  • Butts CA, Socinski MA, Mitchell P et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J. Clin. Oncol. 31( Suppl.), Abstract 7500 (2013).
  • Schimanski CC, Mohler M, Schon M et al. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. BMC Cancer 12, 144 (2012).
  • Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol. 33(7), 364–372 (2012).
  • Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47–64 (2001).
  • Jensen FC, Savary JR, Diveley JP, Chang JC. Adjuvant activity of incomplete Freund’s adjuvant. Adv. Drug Deliv. Rev. 32(3), 173–186 (1998).
  • Bot A, Marincola F, Smith KA. Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. Expert Rev. Vaccines 12(10), 1219–1234 (2013).
  • Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43(3), 204–209 (2010).
  • Clive KS, Tyler JA, Clifton GT et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev. Vaccines 9(5), 519–525 (2010).
  • Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J. 16(4), 382–391 (2010).
  • Zom GG, Khan S, Filippov DV, Ossendorp F. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv. Immunol. 114, 177–201 (2012).
  • Rossi A, Maione P, Schettino C et al. Non-small-cell lung carcinoma vaccines in clinical trials. Expert Rev. Vaccines 10(6), 887–897 (2011).
  • Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30(17), 2046–2054 (2012).
  • Dutoit V, Herold-Mende C, Hilf N et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135(Pt 4), 1042–1054 (2012).
  • Nakagawa K, Noguchi Y, Uenaka A et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin. Cancer Res. 11(15), 5496–5503 (2005).
  • Ohue Y, Eikawa S, Okazaki N et al. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int. J. Cancer 131(5), e649–e658 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.